Evidence map›Paper›PMID 42481749›Full record

ArticleCommunications chemistry2026

Rapid and energy-efficient ultra-large library screening for drug discovery on a SpiNNaker2 neuromorphic chip.

Johnny Alexander Jimenez Siegert, Florian Kelber, Bernhard Vogginger, Paul Eisenhuth, Max Beining, Vivian Ehrlich, Johannes Partzsch, Christian Mayr, Jens Meiler

Abstract read
In one paragraph

Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Johnny Alexander Jimenez Siegert *Institute for Drug Discovery, Leipzig University, Leipzig, Germany.ORCID http://orcid.org/0009-0009-2820-4287
Florian Kelber *Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Dresden/Leipzig, Germany.ORCID http://orcid.org/0000-0001-7663-5211
Bernhard VoggingerCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Dresden/Leipzig, Germany.ORCID http://orcid.org/0000-0001-9042-5405
Paul EisenhuthInstitute for Drug Discovery, Leipzig University, Leipzig, Germany.ORCID http://orcid.org/0009-0006-7379-5096
Max BeiningInstitute for Drug Discovery, Leipzig University, Leipzig, Germany.ORCID http://orcid.org/0009-0007-9513-822X
Vivian EhrlichInstitute for Drug Discovery, Leipzig University, Leipzig, Germany.
Johannes PartzschInstitute of Circuits and Systems, Dresden University of Technology, Dresden, Germany.ORCID http://orcid.org/0000-0002-6286-5064
Christian MayrCenter for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI), Dresden/Leipzig, Germany. christian.mayr@tu-dresden.de.
Jens MeilerInstitute for Drug Discovery, Leipzig University, Leipzig, Germany. jens@meilerlab.org.ORCID http://orcid.org/0000-0001-8945-193X

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 57616814Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) ScaDS.AI
6 · The paper itself

Abstract

The virtual screening of make-on-demand small molecule libraries can prioritize drug candidates for rapid experimental validation to accelerate pre-clinical drug discovery. As ultra-large libraries grow to billions of compounds, exhaustive screening incurs prohibitive costs and energy consumption. We address this challenge with the neuromorphic SpiNNaker2 system, designed for massively parallel AI tasks. Here, we show the implementation of a ligand-based screening pipeline on a 152-core SpiNNaker2 chip. We adapted feed-forward neural networks trained on 2D molecular descriptors to screen 19 billion molecules from the Enamine REAL space. We benchmarked our approach against an NVIDIA Jetson Orin Nano, a GPU-accelerated low-power AI system. Inference on the SpiNNaker2 chip was approximately 4 times faster, yielding 60% higher overall throughput. Meanwhile, SpiNNaker2 consumed about 86% less energy. These results provide a foundation for the deployment of SpiNNaker2 high performance computing clusters and establish application-specific hardware as a scalable and sustainable avenue for cheminformatics.

Identifiers

PMID42481749
PMCPMC13388991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.